Related Experiment Video

Updated: Sep 20, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Ulrich Jaeger1, Constantine S Tam2, Peter Borchmann3

  • 1Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, and Comprehensive Cancer Center, Vienna, Austria.

Blood Advances
|June 10, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

816

Related Experiment Videos

Last Updated: Sep 20, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

816

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Immunocomplex capture fluorescence analysis for donor selection in HLA-haploidentical peripheral blood stem cell transplantation.

Transplant immunology·2026

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Nature medicine·2026

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

International journal of clinical oncology·2026

Deep learning representations of human Immune Health for precision immunology.

bioRxiv : the preprint server for biology·2026

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Transplantation and cellular therapy·2026

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Blood·2026

Central Nervous System Involvement in Children with Hemophagocytic Lymphohistiocytosis: an HLH-2004 Study Report.

Blood advances·2026

Risk Factors for Pediatric Acute Chest Syndrome Utilizing Machine Learning Techniques.

Blood advances·2026

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Blood advances·2026

Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.

Blood advances·2026

Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.

Blood advances·2026

A Comprehensive Review of T-Cell Lymphoma Following CAR T-Cell Immunotherapy.

Blood advances·2026

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms.

The Journal of dermatology·2026

Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.

Apoptosis : an international journal on programmed cell death·2026

Intersession reliability of transcranial magnetic stimulation measures of interhemispheric inhibition.

Neuroscience·2026

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Frontiers in oncology·2026

Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.

Nature reviews. Cancer·2026

Circulating levels of TL1A and its decoy receptor DcR3 in systemic sclerosis.

Clinical rheumatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us